From Gene to Therapy in Spinal and Bulbar Muscular Atrophy: Are We There Yet?
July 2017
in “
Molecular and Cellular Endocrinology
”
Studysummary The authors reviewed the mechanisms behind Kennedy's disease, noting advances in therapeutic strategies such as androgen deprivation and gene silencing that may soon expand treatment options for this incurable neuromuscular condition.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document from April 2018 reviews the genetic causes, pathogenesis, and potential treatments for spinal and bulbar muscular atrophy (SBMA), a neuromuscular condition caused by abnormal expansions in the androgen receptor (AR) gene. It explains how the disease leads to muscle weakness and atrophy, and discusses the role of heat shock proteins and post-translational modifications of AR in disease progression. The paper also explores therapeutic strategies, including androgen deprivation, gene silencing, and targeting muscle tissue, but notes that no disease-modifying treatment was available at the time. Clinical trials had been conducted with mixed results, and while preclinical models showed promise with certain small molecules and RNA interference strategies, challenges remained in translating these findings into effective treatments for patients. The document concludes that further research is needed to understand SBMA's molecular mechanisms and to develop successful therapies.
